KR20130100918A - Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능 - Google Patents

Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능 Download PDF

Info

Publication number
KR20130100918A
KR20130100918A KR1020127032811A KR20127032811A KR20130100918A KR 20130100918 A KR20130100918 A KR 20130100918A KR 1020127032811 A KR1020127032811 A KR 1020127032811A KR 20127032811 A KR20127032811 A KR 20127032811A KR 20130100918 A KR20130100918 A KR 20130100918A
Authority
KR
South Korea
Prior art keywords
antibody
seq
ser
lymphoma
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127032811A
Other languages
English (en)
Korean (ko)
Inventor
슈테판 스틸겐바우어
토르슈텐 젠츠
칼-하인츠 하이더
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130100918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20130100918A publication Critical patent/KR20130100918A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020127032811A 2010-07-16 2011-07-15 Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능 Ceased KR20130100918A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10169795.1 2010-07-16
EP10169795 2010-07-16
EP10175586 2010-09-07
EP10175586.6 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (1)

Publication Number Publication Date
KR20130100918A true KR20130100918A (ko) 2013-09-12

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127032811A Ceased KR20130100918A (ko) 2010-07-16 2011-07-15 Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능

Country Status (15)

Country Link
US (3) US20120189618A1 (enExample)
EP (2) EP2593479A1 (enExample)
JP (2) JP2013538790A (enExample)
KR (1) KR20130100918A (enExample)
CN (2) CN105749276A (enExample)
AU (1) AU2011278227B2 (enExample)
BR (1) BR112013001012A2 (enExample)
CA (1) CA2799036A1 (enExample)
CL (1) CL2013000101A1 (enExample)
EA (1) EA025365B1 (enExample)
IL (1) IL222775A (enExample)
MX (1) MX341463B (enExample)
NZ (2) NZ603161A (enExample)
PH (1) PH12013500118A1 (enExample)
WO (1) WO2012007576A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
JP2015517511A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
AU2016248947B2 (en) 2015-04-13 2020-07-16 Pfizer Inc. Chimeric Antigen Receptors targeting B-Cell Maturation Antigen
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN110461363B (zh) * 2017-03-16 2024-04-02 综合医院公司 靶向cd37的嵌合抗原受体
IL269645B2 (en) 2017-03-31 2025-05-01 Genmab Holding B V Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
WO2020070313A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
WO2025083205A1 (en) 2023-10-18 2025-04-24 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
WO2009023386A2 (en) * 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
AU2009234277B2 (en) * 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2358390A1 (en) * 2008-11-13 2011-08-24 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic combination therapies and uses thereof

Also Published As

Publication number Publication date
CN103003309A (zh) 2013-03-27
NZ603161A (en) 2015-02-27
EA025365B1 (ru) 2016-12-30
JP2013538790A (ja) 2013-10-17
PH12013500118A1 (en) 2013-03-11
CA2799036A1 (en) 2012-01-19
CN105749276A (zh) 2016-07-13
US20150266967A1 (en) 2015-09-24
IL222775A0 (en) 2012-12-31
CL2013000101A1 (es) 2013-12-27
EP2593479A1 (en) 2013-05-22
AU2011278227A1 (en) 2012-11-15
WO2012007576A1 (en) 2012-01-19
EP3252077A1 (en) 2017-12-06
MX341463B (es) 2016-08-22
IL222775A (en) 2017-10-31
BR112013001012A2 (pt) 2016-05-24
AU2011278227B2 (en) 2017-03-02
NZ703225A (en) 2016-11-25
JP2017019800A (ja) 2017-01-26
EA201201660A1 (ru) 2013-07-30
US20130236454A1 (en) 2013-09-12
US20120189618A1 (en) 2012-07-26
MX2012013613A (es) 2012-12-17

Similar Documents

Publication Publication Date Title
KR102821932B1 (ko) 항-ccr8 항체 및 이의 용도
AU2011278227B2 (en) Superior efficacy of CD37 antibodies in CLL blood samples
JP6457431B2 (ja) 抗アクチビンａ抗体およびその使用
TWI679021B (zh) 無海藻糖基化抗fgfr2iiib抗體
KR101745230B1 (ko) Pan-ELR+ CXC 케모카인 항체
TW201132353A (en) WISE binding agents and epitopes
JPH11507535A (ja) 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP2010502740A5 (enExample)
CN102421802A (zh) 人源化的axl抗体
EP3825330A1 (en) Anti-cd117 antibodies and methods of use thereof
CN105431455A (zh) 抗激活素a化合物对受试者的施用
WO2007064911A1 (en) Anti-mouse cd20 antibodies and uses thereof
CN119569881B (zh) 抗cd39抗体及其用途
JP7075135B2 (ja) 増殖因子を標的とする二機能性分子を使用したがんの治療方法
EP3915641A1 (en) Anti-cd5 antibodies and methods of use thereof
EP4377342A1 (en) Humanized anti-human beta ig-h3 protein and uses thereof
CN114787188A (zh) 用抗pd-1抗体治疗癌症的方法
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
CN117015398A (zh) 治疗炎性皮肤病症的方法
HK40000997B (en) Pan-elr+ cxc chemokine antibodies
HK40000997A (en) Pan-elr+ cxc chemokine antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160715

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170918

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180327

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170918

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I